Dr. Xiong Ying, associate chief physician, entered Department of Gynecological Cancer at Sun Yat-sen University Cancer Center in 1996. He served as the associate chief physician and advisor of master’s degree student in 2008. After coming back to China from Japan in 2005, he carried out the Okabayashi's radical hysterectomy, the systematic para-aortic lymphadenectomy and the resection for para-aortic tumor metastasis or recurrence by combining the foreign operation methods and techniques and on the basis of his proficient skills in conventional operations for common malignant gynecological tumors, such as cervical cancer, endometrial cancer, ovarian cancer and vulvar cancer. He has mastered the techniques of radical hysterectomy, pelvic lymphadenectomy and transvaginal hysterectomy through the learning of laparoscopic technology and transvaginal operation.

He features the following five technical advantages.
1. He took the lead in practicing the Okabayashi's radical hysterectomy (since 2005) which is characterized by the ultra-radical parametrial tissue resection and vesicocervical ligament resection and minimizes the postoperative pelvic recurrence caused by parametrial tissue residue.

2. He was the first to carry out the ultra-radical pelvic lymphadenectomy (since 2005). In China, the traditional pelvic lymphadenectomy takes the obturator nerve as the bottom boundary and usually leaves over the lymph adipose tissue at the back side of the obturator nerve, which may not lead to radical resection. Additionally, the localization and dissection of parametrial lymph nodes are not emphasized in China. The vascular skeletonization of parametrial lymph nodes can reveal the common metastasis of this group of lymph nodes (especially the solitary metastasis). The ultra-radical pelvic lymphadenectomy incorporates the dissection of the above two groups of lymph nodes into its regular operation scope to minimize the possibility of leaving over metastatic lymph nodes during operation.

3. He is skilled in the systematic para-aortic lymphadenectomy and sacral lymph node dissection (since 2005). In China, these high-risk operations which require the operator to reach a high technical level are only performed in a small number of large hospitals. But they are a regular part of the operations to treat malignant ovarian tumor and endometrial cancer, etc.

4. He is proficient in the laparoscopic radical hysterectomy and pelvic lymphadenectomy (since 2009).

5. He is adept at the nerve-sparing radical hysterectomy (since 2007) which is an improved technique based on Okabayashi's radical hysterectomy. This improved hysterectomy aims to reduce postoperative urine retention. With the innovation and practice of the above-mentioned diverse operation techniques, Xiong Ying has gradually developed his unique style of operations “extensive and radical resection, delicate and fine dissection”. These operation techniques have been widely praised by his gynecological peers through the exchange and promotion across Guangdong Province and in the neighboring provinces during the last few years.

1. Led and completed one program of Guangdong Provincial Department of Science and Technology

2. Participated in and completed three programs of Guangdong Natural Science Foundation

3. Currently involved in two programs of National Natural Science Foundation of China and one program of Guangdong Natural Science Foundation

4. Engaged in clinical work on radical operation for locally advanced malignant tumor and minimally invasive operation for benign and early malignant tumor

1996 Graduated from Sun Yat-sen University of Medical Sciences (the present North Campus of Sun Yat-sen University)

2003 Conferred upon the degree of Master’s Degree in Oncology

2004 Engaged in one-year advanced studies of gynecology at Hokkaido University in Japan with the Sasakawa Medical Scholarship granted by Ministry of Health

2013 Was conferred upon the Doctoral Degree in Oncology

1. Clinical analysis of 8 cases of vulvar Paget's disease. Chinese Journal of Cancer. 2004;23(2)

2. Expression of metastasis suppressor gene KAI1/CD82 in cervical squamous cell carcinoma and its clinical significance. Chinese Journal of Cancer. 2005;24(1)

3. Correlation of serum squamous cell carcinoma antigen with clinic-pathological features and prognosis of squamous cell carcinoma of uterine cervix. Chinese Journal of Obstetrics and Gynecology. 2007;42(1)

4. Prognostic factors for patients with FIGO stage-IB cervical squamous cell carcinoma: Does the tumor size (≤ 4 cm or > 4 cm) really matter? Chinese Journal of Clinical Oncology. 2007;4(2)

5. Prognostic factors of FIGO stage-IB cervical squamous cell carcinoma. Chinese Journal of Clinical Oncology. 2007;34(17)

6. Stratification of prognostic factors for squamous cell carcinoma of the cervix and its clinical significance. Chinese Journal of Clinical Oncology. 2007;34(18)

7. Analysis of recurrence pattern and prognosis of patients with cervical envenoms and pelvic lymph node metastasis. 2008;43(6)

8. Sentinel lymph node detection using methylene blue in patients with early stage cervical cancer. Gynecologic Oncology. 2006;106(1)

9. Clinical analysis of 12 cases of uterine carcinosarcoma. Chinese Journal of Cancer. 2008;27(5)

10. Investigation on the effect of adjuvant chemotherapy for cervical cancer patients following radical hysterectomy. China Cancer. 2002;11(10)

11. Expression of WAF1 gene in epithelial ovarian cancer tissue. Journal of Sun Yat-sen University (Medical Sciences). 2003;24(6)

12. Small cell carcinoma of uterine cervix: a single institution experience. U.S. Chinese Journal of Lymphology and Oncology. 2006;5(4)

13. Clusterin expression predicts survival of invasive cervical carcinoma patients treated with radical hysterectomy and systematic lymphadenectomy. Gynecologic Oncology. 2008;108(3)

14. Clinical characteristics and prognosis of epithelial ovarian cancer in young women. Chinese Journal of Cancer. 2008;27(9)

15. Clinical significance of combined examination of pretreatment serum CYFRA21-1 and SCCAg in cervical cancer patients. Chinese Journal of Cancer. 2009;28(1):82-86

16. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol. 2009;112(1):229-34. Epub 2008 Nov 12.

17. Xiong Y, Cao LP, Rao HL, Cai MY, Liang LZ, Liu JH. Clinical significance of peritumoral lymphatic vessel density and lymphatic vessel invasion detected by D2-40 immunostaining in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2012 Jun;348(3):515-22.

18. Xiong Y, Liang LZ, Cao LP, Min Z, Liu JH. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 2011 Oct;123(1):99-104.

19. Xiong Y, Liu JH, Zheng M, Cao LP, Liang LZ. Use of preoperative clinicopathologic characteristics to identify patients with low-risk cervical cancer suitable for Piver class II radical hysterectomy. Int J Gynaecol Obstet. 2013 Apr 1.

20. Cao L, Huang Q, He J, Lu J, Xiong Y. Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2013 Feb 19.

21. Watari H, Michimata R, Yasuda M, Ishizu A, Tomaru U, Xiong Y, Hassan MK, Sakuragi N. High prevalence of multiple human papillomavirus infection in Japanese patients with invasive uterine cervical cancer. Pathobiology. 2011;78(4):220-6.

22. Zheng M, Huang L, Liu JH, Xiong Y, Li JD, Huang X, He L, Ren YF, Wang HY. Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients. J Surg Oncol. 2011 Oct;104(5):480-5.

23. Huang L, Zheng M, Liu JH, Xiong Y, Ding H, Tang L, Wang HY. Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis. Chin J Cancer. 2010 Apr;29(4):431-5.

24. Xiong Y, Peng XP, Liang LZ, Zheng M, Li JD. Ai Zheng. Clinical significance of combined examination of pretreatment serum CYFRA21-1 and SCCAg in cervical cancer patients. 2009 Jan;28(1):64-7

25. He L, Li JD, Xiong Y, Huang X, Huang L, Lin JX, Zhou Y, Zheng M. Clinicopathological and molecular markers associated with prognosis and treatment effectiveness of endometrial stromal sarcoma: a retrospective study in China. Arch Gynecol Obstet. 2013 Aug 20.

26. Dong P, Kaneuchi M, Xiong Y, Cao L, Cai M, Liu X, Guo SW, Ju J, Jia N, Konno Y, Watari H, Hosaka M, Sudo S, Sakuragi N. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis. 2014 Apr;35(4):760-8.

27. Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, Kudo M, Sakuragi N. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget. 2014 Jul 2.

 

Last updated on: August, 2014 by International Office, Sun Yat-sen University Cancer Center